歌禮制藥：Sagimet Biosciences宣布同類首創FASN抑制劑ASC40 (Denifanstat)治療中度至重度非酒精性脂肪性肝炎(NASH)患者的2b期臨床試驗取得積極期中數據

array(1) { [453569]=> array(2) { [2]=> array(3) { [0]=> string(12) "臨床試驗" [1]=> string(6) "肝炎" [2]=> string(6) "乙醇" } [4]=> array(1) { [0]=> string(19) "同花順7x24快訊" } } }